Business
ASX to rise, Pfizer bolsters vaccine bets – The Australian Financial Review
Australian shares are poised to open lower after Wall Street shares sold off late in the session amid concerns surging virus cases will prompt wider lockdowns.
Pfizer and its partner BioNTech plan to submit the data to other regulatory agencies around the world and submit data from the study to a peer-reviewed scientific journal.
Pfizer reiterated that it expects to make as many as 50 million vaccine doses this year, enough to protect 25 million people, and then produce up to 1.3 billion doses in 2021.
“In my view, what stocks have not fully priced is more likely to be the 6+ month outlook that could benefit from expedited vaccine availability as opposed…
-
General21 hours agoWA government rolls out suite of housing assistance ahead of state budget
-
Noosa News22 hours agoPolice investigate fire at Borrodell Estate winery restaurant near Orange
-
Business24 hours agoHow much upside does Macquarie see for Collins Foods shares?
-
Business23 hours agoLeading brokers name 3 ASX shares to buy today 16 June 2025